of chemokines and their role in inflammations as reported in literature.
Treatment of asthma protein (MBP) and eosinophilic cationic protein should therefore be based on anti-inflammatory (ECP). 15 Both MCP and ECP are cytotoxic for agents rather than bronchodilators. 2 airway epithelium. Azzawi et aL 16 Recently, the number of structurally defined chemoattractants for leukocytes has greatly increased, largely due to the identification of the chemokine superfamily. 28 The name 'chemo- (Fig. 1) . 33 The structural analysis, chromosomal location and biological properties of lymphotactin provide strong evidence that this cytokine represents a new class of chemokine. 34, 35 Although the chemokines In contrast to the cloned receptors described, a promiscuous receptor on red blood cells has been characterized, that binds a wide variety of inflammatory peptides of both the CXC and CC groups within the chemokine superfamily. 41 '69 The human erythrocyte chemokine receptor, which was originally postulated to be a 'sink' for IL-87 binds the CXC chemokines IL-8, MGSA and PF-4, and the CC chemokines MCP-1 and RANTES with equal high affinity. 24 Other experiments show that the RBC-bound Trp57 and may have a structural role. Never-lower binding affinity and activity than fulltheless, the possibility that Phe21 has hydro-length native MCP-1. However, MCP-1, 5-76 phobic or aromatic contacts with the receptor had surprisingly significant activity and bound cannot be ruled out. 6 to the MCP-1 receptor. 6 Further deletions resulted in analogues that had significant bind-
The disulphides ing to the receptor but no functional activity.
Clark-Lewis and co-workers 36 (b) activation of the cell (induced by classical chemoattractants or chemokines) resulting in firm adhesion (mediated through integrin molecules) leading ultimately to (c) extravasation (crawling along the endothelium, diapedesis, and migration into tissues), presumably in response to a chemoattractant gradient. 9 A key feature is that selectin-carbohydrate, chemoattractant-receptor, and integrin-immunoglobulin family interactions act in sequence, not in parallel. This concept has been confirmed by the observation that inhibition of any one of these steps, with e.g. selectin antagonists, gives essentially complete rather than partial, inhibition of neutrophil and monocyte migration. 79 6 They identified a series of variants of the CC chemokine RANTES that are potent receptor antagonists. These molecules are active in the low nanomolar range, and are able to block CC chemokine effects on purified human cells in vitro. Whether these antagonists will also be able to block CC chemokines effects in vivo remains to be elucidated. Thirdly, the production of chemokines can be inhibited by the use of antisense RNA. In this way translation of the mRNA is prevented and thus the production of the target chemokine. Depending on the homology between the nucleotide sequences of different chemokines, this method might be very selective. From these three options, the development of chemokine antagonists seems the most promising, as they have already been shown to be effective in vitro. Furthermore, their use in practice is not limited due to typical constraints, as is the case for antibodies and peptidic compounds.
